Barclays Initiates Coverage of Boston Scientific with Equal-Weight
Fintel reports that on October 7, 2026, Barclays initiated coverage of Boston Scientific (NYSE:BSX) (BATS-CHIXE:BSXD) with a Equal-Weight recommendation.
Boston Scientific Corporation, based in the United States, predominantly operates in the medical devices industry. The company specializes in developing, manufacturing, and marketing a broad range of high-performance medical solutions. Its product lineup addresses various medical conditions and comprises innovations in fields such as interventional cardiology, endoscopy, neuromodulation, and urology. A key project highlights its investment in next-generation technologies that enhance treatment of heart and vascular conditions, particularly through minimally invasive techniques.
On October 6, 2026, the stock closed at $42.19. On October 7, 2026, the latest close was recorded at $41.57. This represents a one-week price change of -4.76% from a baseline close of $43.65 on September 30, 2026. Over a one-month period, the stock experienced a price change of -13.03% from a baseline close of $47.80 on September 4, 2026.
As of October 2, 2026, the current consensus target mean for the stock is $65.02, while the median target is $61.20. This mean target represents an implied change of +56.40%. The prior consensus target mean was $66.41 as of September 14, 2026, reflecting a consensus target revision of -2.10%. In terms of analyst recommendations, the current recommendation period as of September 1, 2026, shows 11 strong buy, 19 buy, and 8 hold recommendations, with 0 sell and 0 strong sell recommendations. This total of 38 recommendations translates to 78.9% positive, 21.1% hold, and 0.0% negative. These figures are identical to the prior recommendation period as of August 1, 2026, which also recorded 11 strong buy, 19 buy, 8 hold, 0 sell, and 0 strong sell recommendations.
Prior to this initiation, Barclays previously maintained an Overweight rating on May 28, 2026. Other recent analyst actions include Citigroup maintaining a Neutral rating on October 5, 2026. Wells Fargo maintained an Equal-Weight rating on September 24, 2026. Oppenheimer maintained an Outperform rating on September 21, 2026. Citigroup downgraded the stock from Buy to Neutral on September 17, 2026. BTIG maintained a Buy rating on September 9, 2026.
Boston Scientific reported its latest earnings on July 29, 2026, with an actual EPS of 0.86 compared to the estimate of 0.8354, representing a positive surprise of +2.94%. Actual revenue for the quarter reached $5,442,000,000.00, exceeding the estimated revenue of $5,415,088,123.00. The company's upcoming earnings announcement is scheduled for October 28, 2026, before the market open.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Equal-Weight | initiated coverage | |
| October 5, 2026 | Citigroup | Neutral | Neutral | maintained |
| September 24, 2026 | Wells Fargo | Equal-Weight | Equal-Weight | maintained |
| September 21, 2026 | Oppenheimer | Outperform | Outperform | maintained |
| September 17, 2026 | Citigroup | Buy | Neutral | downgrade |
| September 9, 2026 | BTIG | Buy | Buy | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.